LDL Apheresis as a Novel Adjunctive Therapy for Recurrent FSGS After Kidney Transplantation (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1166; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Steroids, PLEX, and Rituximab showed partial response...More data is needed to determine if LDL-A removes the circulating factor in recurrent FSGS, or if it has anti-inflammatory effects. Response to LDL Aphersis"
Chronic Kidney Disease • Dyslipidemia • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Metabolic Disorders • Nephrology • Transplantation • APOB
|
|
Haritha Karuparti; Laila S. Lakhani; George C. Eboh; Terra Davis; David Wojciechowski
|